The management of a patient with a post-radiation pancreatitis is reported. Several biopsies and imaging failed to diagnose the radiation-induced carcinoma revealed during emergency laparotomy. This diagnosis must be kept in mind, and repeated biopsies are necessary.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.clinre.2011.11.012 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Adaptive radiotherapy (ART) involves the continuous adaptation of the radiation plan according to patient- and tumor-specific feedback. In online ART, the plan is optimized in real time during the treatment; in offline ART, the plan is recalculated between treatment sessions. Hybrid linear accelerators with integrated CT, MRI, or PET are required to perform online ART.
View Article and Find Full Text PDFOlaparib and Radiotherapy Induce Type I Interferon- and CD8+ T Cell-Dependent Sensitization to Immunotherapy in Pancreatic Cancer.
Mol Cancer Ther
December 2024
Department of Radiation Oncology, University of Michigan Rogel Cancer Center, Ann Arbor, Michigan.
PARP inhibitors sensitize pancreatic ductal adenocarcinoma (PDAC) to radiation by inducing DNA damage and replication stress. These mechanisms also have the potential to enhance radiation-induced type I interferon (T1IFN)-mediated antitumoral immune responses. We hypothesized that the PARP inhibitor olaparib would also potentiate radiation-induced T1IFN to promote antitumor immune responses and sensitization of otherwise resistant PDAC to immunotherapy.
View Article and Find Full Text PDFSystemic tumor regression with synergy therapy: radiotherapy and CAR-T.
Cell Death Discov
November 2024
Department of Hematology and Oncology, Shenzhen University General Hospital, International Cancer Center, Hematology Institution of Shenzhen University, Shenzhen University Health Science Center, Shenzhen Clinical Research Center for hematologic disease, Shenzhen University, Shenzhen, China.
Pancreatic ductal adenocarcinoma (PDAC) is one of the most poorly prognostic digestive tract malignancies. CLDN18.2 CAR-T therapy has recently shown promising clinical effects in PDAC.
View Article and Find Full Text PDFA metabolic switch to the pentose-phosphate pathway induces radiation resistance in pancreatic cancer.
Radiother Oncol
January 2025
The Benjamin Davidai Department of Radiation Oncology, Sheba Medical Center, Derech Sheba 2, Ramat Gan 5265601, Israel; Tel-Aviv University, Chaim Levanon St. 55, Tel Aviv-Yafo 6997801, Israel; Sidney Kimmel Medical College at Thomas Jefferson University, 4201 Henry Ave, Philadelphia, PA 19144, USA. Electronic address:
Purpose: Pancreatic ductal adenocarcinoma (PDAC) is remarkably resistant to standard modalities, including radiotherapy. We hypothesized that metabolic reprogramming may underlie PDAC radioresistance, and moreover, that it would be possible to exploit these metabolic changes for therapeutic intent.
Methods And Materials: We established two matched models of radioresistant PDAC cells by exposing the AsPC-1 and MIAPaCa-2 human pancreatic cancer cells to incremental doses of radiation.
Engineering Radiocatalytic Nanoliposomes with Hydrophobic Gold Nanoclusters for Radiotherapy Enhancement.
Adv Mater
December 2024
Université Grenoble-Alpes, Inserm U1209, CNRS UMR 5309, Institute for Advanced Biosciences, Allée des Alpes, La Tronche, 38700, France.
Chemoradiation therapy is on the forefront of pancreatic cancer care, and there is a continued effort to improve its safety and efficacy. Liposomes are widely used to improve chemotherapy safety, and may accurately deliver high-Z element- radiocatalytic nanomaterials to cancer tissues. In this study, the interaction between X-rays and long-circulating nanoliposome formulations loaded with gold nanoclusters is explored in the context of oxaliplatin chemotherapy for desmoplastic pancreatic cancer.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!